Abstract 761P
Background
Since 2015, docetaxel chemotherapy, combined with ADT, is considered the standard of care in fit men with metastatic hormone-naive prostate cancer (mHNPC), based on data from three phase III trials (GETUG-AFU 15, CHAARTED, and STAMPEDE). No data are currently available regarding activity of treatments used beyond progression after upfront ADT and docetaxel.
Methods
We retrospectively collected data from patients (pts) participating in the GETUG-AFU 15 phase III trial concerning treatments received beyond progression for castration-resistant disease (CRPC) in both arms (ADT and ADT + docetaxel) including treatment efficacy (measured by a PSA decline, physician assessment of clinical benefit, and time to events), and toxicity (NCI-CTC grading).
Results
245 pts received at least one anticancer treatment at CRPC progression. The treatments most frequently used and their efficacy are detailed in the Table. Toxicity was mild, with only rare grade 3-4 events (17%). Median overall survival measured after the onset of CRPC was respectively 2.29 years (IC95% [1.84-2.59]) and 1.97 years (IC95% [1.64-2.73]) in the ADT and ADT + D arms.
Efficacy of treatments used for CRPC
| Treatment used for CRPC (N = 245 pts) | PSA response (ADT vs ADT + D) | Symptomatic response (ADT vs ADT + D) | Median PFS Months (95%CI) (ADT vs ADT + D) | |
|---|---|---|---|---|
| First treatment for CRPC | Docetaxel based chemotherapy (N = 104) | 23/68 (34%) vs 3/18 (17%) | 16/55 (29%) vs 5/17 (29%) | 7.0 (4.3-9.2) vs 4.1 (1.3-5.0) |
| Bicalutamide (N = 61) | 12/28 (43%) vs 4/24 (17%) | 0/12 (0%) vs 3/21 (14%) | 5.1 (3.2-11.7 ) vs 3.2 (2.1-6.9 ) | |
| Abiraterone or Enzalutamide (N = 13) | 1/2 vs 6/9 | 1/2 vs 1/4 | ||
| Second treatment for CRPC | Docetaxel based chemotherapy (N = 49) | 12/17 (71%) vs 0/9 (0%) | 5/17 (29%) vs 5/12 (42%) | 6.0 (4.2-8.5) vs 2.5 (0.9-6.2) |
| Abiraterone or Enzalutamide (N = 34) | 5/7 (71%) vs 4/7 (57%) | 4/8 vs 2/11 | 6.0 (1.0-9.1 ) vs 5.6 (1.0- ) | |
| Mitoxantrone (N = 17) | 0/8 vs 0/4 | 1/6 vs 2/7 | ||
| Platin based chemotherapy (N = 15) | 0/6 vs 1/2 | 4/10 vs 0/1 |
Conclusions
In this retrospective analysis, anticancer activity was suggested with androgen receptor axis-targeted agents even in patients with metastatic prostate cancer treated upfront with ADT + docetaxel. We observed that docetaxel rechallenge had rather limited activity in this setting.
Clinical trial identification
NCT00104715; release date: 2013 Februray (Lancet Oncol)
Legal entity responsible for the study
Unicancer
Funding
French Health Ministry and Institut National du Cancer (PHRC), Sanofi-Aventis, AstraZeneca, and Amgen
Disclosure
F. Joly: Roche, Pfizer, Novartis, Sanofi, Jansen, Astellas.
M. Soulié: Amgen, Astellas, Astra Zeneca, Ferring, Glaxo Smith K, Ipsen, Jansen, Keocyt, Novartis, Pierre Fabre, Sanofi, Takeda, Zambon.
B. Laguerre: Pfizer, Novartis, Jansen.
K. Fizazi: Participation to advisory boards and honorarium : Sanofi, Janssen, Astellas.
All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract